Pencil Biosciences is developing a truly innovative gene editing technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. The technology is small, modular in design, and non-CRISPR in composition.
The Pharmaceutical Licensing Group, in the UK, has been established for 30 years and is the professional association for those active in pharmaceutical and biotechnology business development and licensing.
There are around 200 members in the UK and over a 1000 in affiliated groups in Europe, Canada and Japan. All sectors of the industry are represented including multinationals, medium and small pharmaceutical companies, biotechnology, generic and consumer companies.
The PLG is a not-for-profit organisation and is managed by a committee of licensing and business development executives from member companies. Details of the Committee members and how to contact them can be found by following the Committee link.
The PLG organises meetings within local countries, a bi-annual European meeting and a bi-annual International meeting. Details of all meetings can be found on the Events page and by linking to other PLG sites on the European page.
Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists they work with their clients to answer their R&D questions and de-risk drug development.
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments.
They work with partners developing cancer drugs to help them save time and money and achieve better outcomes during pre-clinical and clinical development. They are also developing tools to support cancer treatment in real world settings
Pictura Bio’s groundbreaking diagnostic platform was born out of a unique combination of medical and technical expertise in virology, biophysics and microscopy from the company’s co-founders, Dr Nicole Robb and Nicolas Shiaelis.
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Contact Precision for Medicine, Oncology and Rare Disease via their website
Research Donors collects, processes and delivers human blood biospecimens that meet the most demanding research requirements. With a diverse community of over 4000 healthy donors, we can meet any donor specification as required by your project.
We collect fresh HLA typed leukopaks, PBMCs, whole blood and other blood derivatives from donors who have been serologically screened and provided full consent for their samples to be used in commercial and genetic research. Delivery is same day of collection (in certain parts of UK) or next day of collection across the rest of UK and Europe. Soon, we will also be able to procure disease biospecimens.
Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges.
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.
